title: Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction?
abstract: Advances in our knowledge of the molecular mechanisms involved in cancer biology have contributed to an increase in novel target-specific oncology therapeutics. Unfortunately, clinical development of new drugs is an expensive and slow process, and the patient and financial resources needed to study the vast number of potential therapies are limited, requiring novel approaches to clinical trial design and patient recruitment. In addition, traditional efficacy endpoints may not be adequate to fully determine the therapeutic worth of the new classes of targeted agents. In this new era of drug development, it has become increasingly clear that new clinical trial design paradigms that examine nontraditional endpoints have become necessary to assist in prioritizing the development of the most promising agents. It is also vital that individual patient management be considered, and the subpopulations of patients most likely to derive benefit or experience harm from a new therapy be identified as early as possible. Phase I and II clinical trials allow investigators doing clinical research the opportunity to define these critical endpoints and subpopulations early on, before conducting large-scale randomized phase III clinical trials, which require an abundance of financial and patient resources.
authors.affiliation: Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA. lorussop@karmanos.org
authors.forename: Patricia M
authors.initials: PM
authors.lastname: LoRusso
authors.forename: Aparna B
authors.initials: AB
authors.lastname: Anderson
authors.forename: Scott A
authors.initials: SA
authors.lastname: Boerner
authors.forename: Steven D
authors.initials: SD
authors.lastname: Averbuch
mesh_terms: D017321:Clinical Trials, Phase I as Topic / Q000379:methods / Q000639:trends; D017322:Clinical Trials, Phase II as Topic / Q000379:methods / Q000639:trends; D015507:Drugs, Investigational / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D004526:Efficiency; D006801:Humans; D008495:Medical Oncology / Q000379:methods* / Q000639:trends*; D009369:Neoplasms / Q000628:therapy*; D011364:Professional Practice / Q000639:trends*; D035703:Therapies, Investigational / Q000379:methods / Q000639:trends; D016896:Treatment Outcome
chemical_list: D015507:Drugs, Investigational